Conclusion

“Before beginning any form of treatment of OIC, it is important to take a complete history, because not all patients taking opioids and experiencing constipation necessarily have OIC,” Dr. Chey advises. “The development of constipation temporally associated with opioid treatment initiation is likely caused by opioids.”

“If lifestyle changes, osmotics, or stimulants are ineffective, I would advise considering treatment with a PAMORA sooner rather than later,” he adds.


Continue Reading

At present, there are no consensus guidelines for management of OIC. The American Academy of Pain Medicine has convened a panel of experts who are currently drafting guidelines, says Dr. Fudin, who is a member of the panel.

Dr. Fudin notes that the absence of guidelines means “it is difficult to get managed care to pay for PAMORAs, since they are not currently regarded as standard of care.” It is to be hoped that this will change once guidelines have been established.

References

  1. Centers for Disease Control and Prevention (CDC). Vital Signs. Opioid painkiller prescribing. (2014) Available at: http://www.cdc.gov/vitalsigns/opioid-prescribing/. Accessed: May 18, 2015.
  2. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387-2396.
  3. Neefjes EC, van der Vorst MJ, Boddaert MS, et al. Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliat Care. 2014;13:42.
  4. Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014;2014:141737.
  5. Lee YY. What’s New in the Toolbox for Constipation and Fecal Incontinence? Front Med. 2014;1:5.
  6. Wilson N, Schey R. Lubiprostone in constipation: clinical evidence and place in therapy. Ther Adv Chronic Dis. 2015;6(2):40-50.
  7. Leppert W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Des Devel Ther. 2015;9:2215-2231.
  8. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009; 13(1):56-64.
  9. Leppert W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep. 2010;62(4):578-591.
  10. US Food and Drug Administration (FDA). FDA approves new extended-release oxycodone with abuse-deterrent properties. (2014) Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406407.htm. Accessed: May 17, 2015.
  11. Bader S, Dürk T, Becker G. Methylnaltrexone for the treatment of opioid-induced constipation. Expert Rev Gestroenterol Hepatol. 2013;7(1):13–26.
  12. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-2343.
  13. Lipman AG, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study. J Pain Palliat Care Pharmacother. 2011;25(2):136-145.
  14. Entereg (alvimopan) capsules . Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) Silver Spring, MD: US Food and Drug Administration; [Accessed July 22, 2014]. [updated October 2013]. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/ucm194328.htm.
  15. US Food and Drug Administration (FDA). FDA approves Movantik for opioid-induced constipation. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm414620.htm. Accessed: May 16, 2015.